1. Home
  2. TRDA vs ACCO Comparison

TRDA vs ACCO Comparison

Compare TRDA & ACCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$11.67

Market Cap

404.4M

Sector

Health Care

ML Signal

HOLD

Logo Acco Brands Corporation

ACCO

Acco Brands Corporation

HOLD

Current Price

$4.04

Market Cap

346.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
ACCO
Founded
2016
1893
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Publishing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
404.4M
346.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
TRDA
ACCO
Price
$11.67
$4.04
Analyst Decision
Strong Buy
Buy
Analyst Count
1
1
Target Price
$20.00
$6.00
AVG Volume (30 Days)
200.0K
601.8K
Earning Date
02-26-2026
02-19-2026
Dividend Yield
N/A
7.43%
EPS Growth
N/A
N/A
EPS
N/A
0.43
Revenue
$61,520,000.00
$1,544,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.14
$3.53
P/E Ratio
N/A
$9.35
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$3.20
52 Week High
$14.27
$5.68

Technical Indicators

Market Signals
Indicator
TRDA
ACCO
Relative Strength Index (RSI) 64.79 62.65
Support Level $10.34 $3.93
Resistance Level $11.49 $4.15
Average True Range (ATR) 0.72 0.11
MACD 0.08 0.01
Stochastic Oscillator 83.51 77.69

Price Performance

Historical Comparison
TRDA
ACCO

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About ACCO Acco Brands Corporation

ACCO Brands Corp designs, manufactures, and markets consumer and business products. It operates through two segments: ACCO Brands Americas, and ACCO Brands International. The company offers school notebooks, janitorial supplies, and whiteboards; storage and organization products, sheet protectors, and indexes, and punching products; computer accessories and others used in schools, homes, and businesses. The company markets and sells its products through various channels, including mass retailers; e-tailers; discount, and variety chains; and warehouse clubs. It generates maximum profit from ACCO Brands America segment.

Share on Social Networks: